Company intelligence / Profile preview

BioMimetix

Greenwood Village, Colorado, United Statesbiomimetixpharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

BioMimetix’s lead compound BMX‑001 has demonstrated increased median survival by 6.6 months in high-grade glioma patients when combined with radiotherapy and temozolomide. The drug also reduced radiation-induced cognitive issues and improved white matter integrity. The company is preparing for a pivotal Phase 3 trial after completing promising Phase 2 data. BMX‑001 has received FDA Breakthrough Therapy designation for this indication

Therapeutic areas: OncologyDermatology
Modalities: Small molecules (specifically redox-active metalloporphyrins)
Industry: Biotech

Drug pipeline

1 asset

BMX-001

Phase 2

Indications: High-grade glioma, Cancer

Beyond the preview

Go deeper on BioMimetix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioMimetix.

Explore the full profile